Publication | Closed Access
Discovery and Development of Selective M3 Antagonists for Clinical Use
29
Citations
0
References
1998
Year
PharmacotherapyExperimental PharmacologyTranslational PharmacologyPre-clinical PharmacologyDrug ResistanceMolecular PharmacologySelective M3 AntagonistsRenal PharmacologySelective AntagonistsHealth SciencesUrological ResearchMechanism Of ActionPharmacological AgentNon-peptide LigandPharmacologyUrologyPhysiologyClinical PharmacologyUrologyurological SurveyMedicineDrug Discovery
No AccessJournal of UrologyUrological Survey: Abstracts: Voiding Function and Dysfunction, and Female Urology1 Jun 1998Discovery and Development of Selective M3 Antagonists for Clinical Use V.A. Alabaster V.A. AlabasterV.A. Alabaster More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)63362-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Discovery and Development of Selective M3 Antagonists for Clinical Use." The Journal of Urology, 159(6), pp. 2261–2262 Department of Discovery Biology, Pfizer Central Research, Kent, United Kingdom© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Bradshaw B, Evans P, Fletcher J, Lee A, Mwashimba P, Oehlrich D, Thomas E, Davies R, Allen B, Broadley K, Hamrouni A and Escargueil C (2008) Synthesis of 5-hydroxy-2,3,4,5-tetrahydro-[1H]-2-benzazepin-4-ones: selective antagonists of muscarinic (M3) receptorsOrganic & Biomolecular Chemistry, 10.1039/b801206g, VOL. 6, NO. 12, (2138), . Volume 159Issue 6June 1998Page: 2261-2262 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.MetricsAuthor Information V.A. Alabaster More articles by this author Expand All Advertisement PDF downloadLoading ...